Which has the lower trailing P/E, CAI or TGTX?

TGTX has the lower trailing P/E: CAI trades at 76.71 and TGTX at 19.05. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CAI or TGTX?

Over the past five years, TGTX grew revenue faster — CAI at a 26.15% CAGR versus TGTX at 219.22%.

Is CAI or TGTX more profitable?

TGTX runs the higher net margin — CAI at 10.62% versus TGTX at 55.22%.

Caris Life Sciences, Inc. (CAI) vs TG Therapeutics, Inc. (TGTX)

A side-by-side comparison of Caris Life Sciences, Inc. and TG Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CAI

Caris Life Sciences, Inc.

$7.76B

$27.46HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

TGTX

TG Therapeutics, Inc.

$7.99B

$52.19HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CAI vs TGTX

growth of $100 · dividends reinvested · last 1y

CAI +8.5% (+8.5%/yr)TGTX +54.0% (+54.0%/yr)TGTX compounded faster over this window

CAI TGTX

CAI vs TGTX: by the numbers

•TGTX is the larger company ($7.99B vs $7.76B market cap).
•TGTX trades at the lower trailing earnings multiple (19.05 vs 76.71 P/E), one valuation lens rather than an overall verdict.
•TGTX converts more revenue to profit (55.22% vs 10.62% net margin).
•TGTX grew revenue faster over the past five years (219.22% vs 26.15% CAGR).

Metrics side by side

Valuation

Metric	CAI	TGTX
P/E ratio	76.71	19.05
Forward P/E	236.62	53.62
P/S ratio	7.84	9.99
P/B ratio	13.12	13.23
EV / EBITDA	43.23	60.46
FCF yield	1.89%	0.22%

Profitability

Metric	CAI	TGTX
Gross margin	69.66%	82.36%
Operating margin	5.56%	17.05%
Net margin	10.62%	55.22%
ROE	17.77%	73.08%
ROIC	14.76%	9.94%

Growth (annualized)

Metric	CAI	TGTX
Revenue CAGR (5Y)	26.15%	219.22%
Total return CAGR (5Y)	N/A	10.75%

Frequently asked

Which has the lower trailing P/E, CAI or TGTX?: TGTX has the lower trailing P/E: CAI trades at 76.71 and TGTX at 19.05. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CAI or TGTX?: Over the past five years, TGTX grew revenue faster — CAI at a 26.15% CAGR versus TGTX at 219.22%.
Is CAI or TGTX more profitable?: TGTX runs the higher net margin — CAI at 10.62% versus TGTX at 55.22%.

Go deeper

Full CAI analysis Full TGTX analysis Interactive comparison tool

Dig into the metrics

Caris Life Sciences P/E ratio TG Therapeutics P/E ratio Caris Life Sciences ROE TG Therapeutics ROE Caris Life Sciences operating margin TG Therapeutics operating margin Caris Life Sciences revenue growth TG Therapeutics revenue growth Caris Life Sciences free cash flow TG Therapeutics free cash flow

Caris Life Sciences & TG Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.